Journal
ONCOTARGET
Volume 6, Issue 32, Pages 34014-34022Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.5607
Keywords
KRAS; NSCLC; platinum; first-line
Categories
Funding
- Agenzia Italiana del Farmaco [FARM6F5JER]
- Fondazione CARIPLO [2010-0794]
- AIRC [IG-12915]
Ask authors/readers for more resources
KRAS mutations seem to indicate a poor outcome in Non-Small-Cell Lung Cancer (NSCLC) but such evidence is still debated. The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy. Patients (N = 540), enrolled in the study in 52 Italian hospitals, were centrally genotyped twice in two independent laboratories for EGFR and KRAS mutational status. Of these, 247 patients were eligible and included in the present study. The primary endpoint was overall survival (OS) according to KRAS mutational status in patients harboring EGFR wild-type. Sixty (24.3%) out of 247 patients harbored KRAS mutations. Median OS was 14.3 months and 10.6 months in wild-type and mutated KRAS patients, respectively (unadjusted Hazard Ratio [HR]= 1.41, 95% Confidence Interval [CI]: 1.03-1.94 P = 0.032; adjusted HR= 1.39, 95% CI: 1.00-1.94 P = 0.050). This study, with all consecutive patients genotyped, indicates that the presence of KRAS mutations has a mild negative impact on OS in advanced NSCLC patient treated with a first-line platinum-containing regimen.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available